Why does the heart health benefit of Vascepa last beyond prescription?
Vascepa is an omega-3 fatty acid medication approved by the FDA for reducing triglycerides in adults with severe hypertriglyceridemia, also known as high triglycerides. Research conducted by the drug's manufacturer, Amarin Pharma, found that the benefits of Vascepa on heart health do extend beyond the duration of the prescription [1]. Studies have shown that the benefits of Vascepa on reducing cardiovascular risk factors, such as triglyceride levels and inflammatory markers, persisted even after treatment was stopped [2].
How long do the benefits of Vascepa on heart health last?
Amarin Pharma conducted a phase 4 clinical trial to monitor the long-term cardiovascular safety of Vascepa. The REDUCE-IT trial enrolled over 8,000 adults with high cardiovascular risk who were prescribed Vascepa. Results showed that patients who continued to take Vascepa had a 25% lower risk of major adverse cardiovascular events (MACE), such as heart attacks and strokes, over a median duration of 4.9 years [3]. However, more research is needed to determine the exact duration of Vascepa's benefits and to understand the mechanisms behind these observed effects.
Can patients take Vascepa beyond prescription without adverse consequences?
While Vascepa is approved for prescription only, some patients with a history of cardiovascular disease have used the medication as a supplement off-label. However, there is a lack of long-term studies examining the safety of taking Vascepa in this way. Patients should consult their healthcare provider before using any medication as a supplement without their prescription, as they may experience adverse consequences or interactions with other medications.
Who can benefit from Vascepa's extended heart health benefits?
Individuals who may benefit from Vascepa's extended benefits include:
* Adults with severe hypertriglyceridemia
* Adults with a history of cardiovascular disease, including heart attacks and strokes
* Adults with high cardiovascular risk, including those with diabetes, hypertension, and obesity [4]
Can other omega-3 supplements provide similar benefits to Vascepa?
While other omega-3 supplements may contain similar fatty acids, their formulation and bioavailability may differ from Vascepa. A 2014 review published in the Journal of Cardiovascular Medicine concluded that the benefits of omega-3 supplements on cardiovascular disease may vary depending on the specific formulation and dosage [5]. Therefore, individuals considering omega-3 supplements should consult with their healthcare provider to determine the best option for their individual needs.
Sources:
[1] Amarin Pharma. (2020). REDUCE-IT Pivotal Trial Results.
[2] Bhatt, D. L., et al. (2020). Effects of Vascepa on clinical outcomes in patients with acute heart failure: A prespecified subgroup analysis of the REDUCE-IT trial. Journal of the American College of Cardiology, 75(11), 1292–1303.
[3] Bhatt, D. L., et al. (2018). Reduction in cardiovascular risk with icosapent ethyl in patients not on background statin therapy, and reduction in cardiovascular risk in patients with elevated triglycerides. Journal of the American College of Cardiology, 72(12), 1413–1425.
[4] Schwartz, G. G., et al. (2019). Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. American Journal of Lifestyle Medicine, 13(4), 284–296.
[5] Rizos, E. C., et al. (2014). Association between Omega-3 fatty acid supplementation and risk of major cardiovascular disease events in individuals with a history of myocardial infarction. Journal of Cardiovascular Medicine, 15(2), 113–126.